FDA Clearance Tracker · P180008
t:slim X2 Insulin Pump with Basal-IQ Technology
Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jun 21, 2018
Approved
Time to decision
115 days
Received Feb 26, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P180008
- Device name
- t:slim X2 Insulin Pump with Basal-IQ Technology
- Applicant
- Tandem Diabetes Care, Inc.
- Applicant location
- San Diego, CA
- Received
- Feb 26, 2018
- Decided
- Jun 21, 2018
- Decision
- Approved
- Supplements
- 6 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the use of the t:slim X2 Insulin Pump with Basal-IQ Technology. This device is indicated as follows:The t:slim X2 Insulin Pump with Basal-IQ Technology (the System) consists of the t:slim X2 Insulin Pump which contains the Basal-IQ technology, and a continuous glucose monitor (CGM). Compatible CGMs include the Dexcom G5 Mobile CGM and integrated continuous glucose monitors (iCGMs) that are listed in the labeling for this device.The t:slim X2 Insulin Pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 Insulin Pump can be used solely for continuous insulin delivery and as part of the t:slim X2 Insulin Pump with Basal-IQ Technology System.When the System is used with the Dexcom G5 Mobile CGM or a compatible iCGM, the Basal-IQ Technology can be used to suspend insulin delivery based on CGM sensor readings. The Dexcom G5 Mobile CGM Continuous Glucose Monitoring System (Dexcom G5) is indicated for the management of diabetes in persons age 2 years and older. The Dexcom G5 is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the System results should be based on the trends and patterns seen with several sequential readings over time. The Dexcom G5 also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. The Dexcom G5 is intended for single patient use and requires a prescription.The System is indicated for use in individuals 6 years of age and greater.The System is intended for single patient use and requires a prescription.The System is indicated for use with NovoLog or Humalog U-100 insulin.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OZO. The earliest in FDA's data is P120010, decided Sep 26, 2013.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Tandem Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Control-IQ+ technology510(k)
K260429 · Decided Apr 24, 2026 · 73 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
K253074 · Decided Nov 6, 2025 · 44 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K250792 · Decided Sep 24, 2025 · 194 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.